<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443882</url>
  </required_header>
  <id_info>
    <org_study_id>01 2018 ver1</org_study_id>
    <nct_id>NCT03443882</nct_id>
  </id_info>
  <brief_title>Bioavailability of Astaxanthin Formulations</brief_title>
  <official_title>Bioavailability of Astaxanthin Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algatechnologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algatechnologies Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioavailability of dietary supplement formulations in healthy volunteers after a single oral
      dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of the bioavailability of 3 formulations with astaxanthin in healthy volunteers
      after single dose
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2018</start_date>
  <completion_date type="Anticipated">August 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma level</measure>
    <time_frame>0-48 hr</time_frame>
    <description>astaxanthin in plasma</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>formulation #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation #3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Astaxanthin</intervention_name>
    <description>an oral dose form</description>
    <arm_group_label>formulation #1</arm_group_label>
    <arm_group_label>formulation #2</arm_group_label>
    <arm_group_label>formulation #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have signed an informed consent form and who meet all of the following
             entrance criteria may be enrolled in this clinical trial: Generally, healthy men and
             women who are 21 to 50 years of age, inclusive, at the baseline visit.

        Exclusion Criteria:

          -  1. Are unwilling to follow the procedures of the trial, such as making visits or
             having their blood drawn.

             2. Have unintentionally lost or gained 10 or more kg of body weight in the last 3
             months; 3. Have an acute illness (such as a severe cold or flu) or have been
             hospitalized within the past month for certain conditions; 4. Have severe co-morbid
             disease including cardiac, pulmonary, renal, hepatic, carotid, peripheral vascular
             disease, stroke, neurological, clotting disorders or active cancer; 5. Taking chronic
             drugs which interfere with lipids metabolism (statins or similar) 6. Consume alcohol
             at an elevated level (Defined as consumption of more than 10 standard alcoholic drinks
             per week. A standard alcoholic drink is defined as one bottle/can of beer or one glass
             of wine equals one portion of hard liquor).

             7. Consume carotenoids as food supplements. 8. Have a Body Mass Index (BMI) of less
             than 17 or greater than 35 m/kg2; 9. Have participated in a clinical trial in the past
             4 weeks; 10. Have any disease or condition that in the investigator's opinion
             compromises the integrity of the clinical trial or the safety of the subject; 11.
             Smokers 12. Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Bitzur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tair Lapidot, PhD</last_name>
    <phone>972-54-8095209</phone>
    <email>tair@algatech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bert W. Strassburger Lipid Center, Sheba Medical Center,</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Luvish</last_name>
      <phone>+972-3-5303492</phone>
      <email>Tamar.luvish@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

